Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12367685 | 0.83 | GAA (0.55) | GAADDB1CRBN | |
| SCHEMBL2176628 | 0.83 | GAA (0.55) | GAADDB1CRBN | |
| SCHEMBL20904043 | 0.78 | GAA (0.47) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL31068584 | 0.78 | GAA (0.52) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL2770955 | 0.76 | GAA (0.49) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL2770869 | 0.76 | GAA (0.49) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL23513495 | 0.75 | GAA (0.59) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4760856 | 0.75 | GAA (0.59) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL14277693 | 0.75 | GAA (0.59) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL3621203 | 0.75 | GAA (0.54) | GAANFKB1NFKB2RELABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | GAA 312/4885NFKB1 290/4885NFKB2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.